School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; Engineering Research Center of Shanghai Colleges for TCM New Drug Discovery, Shanghai 201203, China; National Pharmaceutical Regulatory Agency, Ministry of Health, Lot 36, Jalan University, Petaling Jaya, Selangor 46200, Malaysia.
School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; Engineering Research Center of Shanghai Colleges for TCM New Drug Discovery, Shanghai 201203, China.
Drug Discov Today. 2024 Oct;29(10):104129. doi: 10.1016/j.drudis.2024.104129. Epub 2024 Aug 3.
Cardiac glycosides (CGs), which are traditionally used for heart disease, show promise for cancer therapy. However, there is a lack of a comprehensive review of clinical studies in this area, and so far, CGs have not been widely integrated into clinical cancer treatment. This review covers clinical studies from the past five years, highlighting the potential of CGs to reduce cancer risk, enhance chemotherapy effectiveness, mitigate chemotherapy-induced side effects and improve quality of life. Future clinical trials should personalize the dosage of CGs, integrate molecular testing and investigate immunogenic cell death induction and the potential of CGs for treating bone cancer and metastasis. Optimizing the repurposing of CGs for anticancer treatment requires consideration of specific CGs, cancer types and concurrent medications.
强心苷（CGs）传统上用于心脏病治疗，在癌症治疗方面显示出前景。然而，该领域缺乏对临床研究的全面综述，迄今为止，CGs尚未广泛整合到临床癌症治疗中。本综述涵盖了过去五年的临床研究，强调了 CGs降低癌症风险、增强化疗效果、减轻化疗引起的副作用和提高生活质量的潜力。未来的临床试验应个性化 CGs 的剂量，整合分子检测，并研究免疫原性细胞死亡诱导以及 CGs 治疗骨癌和转移的潜力。为了优化 CGs 用于抗癌治疗的再利用，需要考虑特定的 CGs、癌症类型和同时使用的药物。
